Skip to content

Safety of Remazolam Besylate Combined with sufentanil for Enteroscopy in Obese Patients

Safety of Remazolam Besylate Combined with sufentanil for Enteroscopy in Obese Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300073543
Enrollment
Unknown
Registered
2023-07-13
Start date
2021-02-07
Completion date
Unknown
Last updated
2023-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

enteroscopy

Interventions

Sponsors

Deyang People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) ASA level I-II; (2) Age 18-65 years old, regardless of gender; (3) BMI index between 24 and 32; (4) Voluntarily sign an informed consent form; (5) Those who undergo painless colonoscopy for the first time within 3 months and voluntarily take appropriate and effective contraceptive measures.

Exclusion criteria

Exclusion criteria: (1) The subject explicitly refused to participate in this study; (2) Individuals who are resistant to opioid drugs; (3) Individuals with sleep disorders or mental illnesses before enrollment; (4) Exposure to similar anesthetic drugs within 3 months; (5) Insufficiency of important organs such as heart function, liver function, kidney function, and lung function; (6) There were contraindications of propofol, sufentanil citrate and benzodiazepine in the enrolled patients; (7) Patients with a history of head injury, chest injury, intracranial surgery, or stroke within 4 weeks before surgery, or those with organic lesions of the central nervous system and consciousness disorders; (8) Hypertensive patients whose blood pressure has not been satisfactorily controlled after treatment with antihypertensive drugs (screening period sitting systolic blood pressure = 160mmHg, and/or screening period diastolic blood pressure = 105mmHg); (9) Pregnant or lactating women; (10) Other situations where participants in other clinical trials or researchers consider it inappropriate to enter the experiment within 3 months prior to surgery.

Design outcomes

Secondary

MeasureTime frame
injection pain;hypotension;hypertension;Decreased heart rate;Increased heart rate;apnea;Manually open airway;Kinetic reactionKinetic reaction;anaphylaxis;nausea and vomiting;Dizziness and headache;Drowsiness and fatigue;Abdominal pain and bloating;Patient satisfaction score;

Primary

MeasureTime frame
hypoxemia;

Countries

China

Contacts

Public Contactwang ying

Deyang People's Hospital

16177211@qq.com+86 139 8108 8319

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026